<?xml version='1.0' encoding='utf-8'?>
<document id="28523460"><sentence text="Evaluation of the effect of torsemide on warfarin dosage requirements."><entity charOffset="28-37" id="DDI-PubMed.28523460.s1.e0" text="torsemide" /></sentence><sentence text="Background According to drug interaction databases, torsemide may potentiate the effects of warfarin"><entity charOffset="52-61" id="DDI-PubMed.28523460.s2.e0" text="torsemide" /><entity charOffset="92-100" id="DDI-PubMed.28523460.s2.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.28523460.s2.e0" e2="DDI-PubMed.28523460.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28523460.s2.e0" e2="DDI-PubMed.28523460.s2.e1" /></sentence><sentence text=" Evidence for this drug-drug interaction, however, is conflicting and the clinical significance is unknown" /><sentence text=" Objective The aim of this study is to evaluate the impact of torsemide initiation on warfarin dosage requirements"><entity charOffset="62-71" id="DDI-PubMed.28523460.s4.e0" text="torsemide" /></sentence><sentence text=" Setting This study was conducted at the Veterans Affairs Healthcare System in San Diego, California" /><sentence text=" Method A retrospective cohort study was conducted using Veterans Affairs data from patients who were converted from bumetanide to torsemide between March 2014 and July 2014"><entity charOffset="117-127" id="DDI-PubMed.28523460.s6.e0" text="bumetanide" /><entity charOffset="131-140" id="DDI-PubMed.28523460.s6.e1" text="torsemide" /><pair ddi="false" e1="DDI-PubMed.28523460.s6.e0" e2="DDI-PubMed.28523460.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28523460.s6.e0" e2="DDI-PubMed.28523460.s6.e1" /></sentence><sentence text=" Patients were also prescribed and taking warfarin during the observation period" /><sentence text=" Warfarin dosage requirements were evaluated to determine if any changes occurred within the first 3 months of starting torsemide"><entity charOffset="120-129" id="DDI-PubMed.28523460.s8.e0" text="torsemide" /></sentence><sentence text=" Main outcome measure The primary outcome was the average weekly warfarin dose before and after torsemide initiation"><entity charOffset="96-105" id="DDI-PubMed.28523460.s9.e0" text="torsemide" /></sentence><sentence text=" Results Eighteen patients met study inclusion criteria" /><sentence text=" The weekly warfarin dose before and after initiation of torsemide was not significantly different (34 ± 15 and 34 ± 13 mg, p &gt; 0"><entity charOffset="57-66" id="DDI-PubMed.28523460.s11.e0" text="torsemide" /></sentence><sentence text="05)" /><sentence text=" Of those eighteen patients, only two experienced elevations in INR that required a decrease in warfarin dosage after torsemide initiation"><entity charOffset="118-127" id="DDI-PubMed.28523460.s13.e0" text="torsemide" /></sentence><sentence text=" Between those two patients, dosage reductions ranged from 5" /><sentence text="3 to 18%" /><sentence text=" Conclusion These results indicated that most patients did not require any warfarin dosage adjustments after torsemide was initiated"><entity charOffset="109-118" id="DDI-PubMed.28523460.s16.e0" text="torsemide" /></sentence><sentence text=" The potential for interaction, however, still exists" /><sentence text=" While empiric warfarin dosage adjustments are not recommended when initiating torsemide, increased monitoring is warranted to minimize the risk of adverse effects"><entity charOffset="79-88" id="DDI-PubMed.28523460.s18.e0" text="torsemide" /></sentence><sentence text="" /></document>